Form 4: Ironwood Pharmaceuticals Director Julie McHugh Sells Shares Under 10b5-1 Plan

Director Julie McHugh of Ironwood Pharmaceuticals sold 22,766 shares of Class A Common Stock on June 10, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On June 10, 2024, Julie McHugh, a director of Ironwood Pharmaceuticals, sold 22,766 shares of Class A Common Stock.
• The sale was executed under a Rule 10b5-1 trading plan.
• The shares were sold at a weighted average price of $6.29.
• The prices for individual transactions ranged from $5.95 to $6.55.
• Following the transaction, McHugh directly owns 139,528 shares of Ironwood Pharmaceuticals.
• Brian Tessler, Attorney-in-Fact, signed the Form 4 on June 12, 2024.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing related to a stock sale by a director. It doesn't inherently convey positive or negative sentiment, as it's a routine disclosure.

Industry Context

Sales by insiders are a common occurrence and are often related to personal financial planning. The use of a 10b5-1 plan suggests the insider planned the sale in advance.

Stakeholder Impact

• The sale of shares by a director could have a minor impact on shareholder confidence, but the use of a 10b5-1 plan mitigates concerns about insider trading.

Key Dates